Get started

PFIZER

PFIZER INC: FUNDAMENTAL ANALYSIS REPORT+NEXT TARGET|MUST READ 🔔Late last month, Pfizer announced that its drug abrocitinib had been approved by Japan's Ministry of Health, Labor and Welfare (MHLW) as a treatment for patients aged 12 and older with moderate to severe atopic dermatitis or eczema. The Japanese approval of abrocitinib under the trade name Cibinqo came just weeks after the UK Medicines and Healthcare Products Regulatory Agency (MHRA) approved the drug for adults and adolescents with moderate to severe eczema. Let's take a look at why the MHLW approved the drug for use in eczema, as well as its sales potential and what it means for Pfizer. Typically, first-line therapy for eczema patients is topical corticosteroids (TCS), which are effective in treating most eczema patients. But for the large minority of eczema patients who do not experience significant benefits from TCS, there is a huge unmet medical need. And this is where Pfizer's Cibinqo can make a big difference in treating complex eczema cases. For context, the leading eczema drug is Dupixent, which was developed jointly by Regeneron and Sanofi. Dupixent is also approved as a complementary treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, bringing the drug's sales to more than $8 billion last year. And although Pfizer will release the full results of the drug's latest phase 3 trial later, Cibinqo was found to outperform Dupixent in all measures of efficacy. More patients who received 200 milligrams of Cibinqo once daily compared to 300 mg of Dupixent once every two weeks reported a four-point improvement in peak itch severity on the numeric rating scale in the second week of treatment compared to baseline levels before treatment. Simply put, the Peak Itch Digital Rating Scale is used by health care providers to measure the intensity of itching in patients with moderate to severe eczema. Although full study data have not yet been published, Cibinqo has demonstrated greater efficacy than Dupixent in reducing itching in patients with eczema in the second week of treatment. This should lead to an improvement in the quality of life of eczema patients. With a better understanding of Cibinqo's effectiveness in treating eczema, we can now explore the sales potential of this drug for Pfizer. Cibinqo's Phase 3 clinical trial showing higher efficacy compared to Dupixent is certainly an advantage. However, in the coming months, when Pfizer presents additional data, it will become clear how much of an efficacy advantage Cibinqo has over Dupixent. This is because last month the U.S. Food and Drug Administration (FDA) issued new warnings for Janus kinase inhibitors such as Cibinqo. This may encourage health care providers worldwide to exercise caution when prescribing Cibinqo in favor of Dupixent if the benefits are deemed to outweigh the risks compared to Dupixent. The encouraging news for Cibinqo is that, at first glance, the percentage of patients who discontinued Cibinqo was similar to those who discontinued Dupixent because of adverse events. There are approximately 105 million adults in Japan, and given that the prevalence of eczema among adults is estimated at 6.5%, there are 6.8 million adults with eczema. Since 23.3% of eczema cases in Japan are estimated to be moderate to severe, there are about 1.6 million adults with moderate to severe eczema. Of these 1.6 million, about 19% will not be able to control their symptoms with TCS alone. Thus, the real market of adult patients in Japan with moderate to severe eczema for Cibinqo is about 300,000. Cibinqo is expected to win 10% or 30,000 of these patients, which conservatively accounts for the remaining efficacy and safety issues of Cibinqo compared to the leader Dupixent. Since the Institute for Economic and Clinical Analysis estimates that the annual price in the United States is between $30,000 and $40,000, and prescriptions in Japan are on average 43% cheaper than in the United States, Cibinqo would have a net price of $10,000 per year. Thus, this eczema indication should generate about $300 million in annual revenue for Pfizer in Japan alone. Although this is a fraction of a percent compared to Pfizer's expected revenue of $78 billion to $80 billion this year, it is a good additional income for the company. Although Cibinqo looks like a promising new drug for Pfizer, the company is not idly waiting for results. While established drugs such as the COVID-19 Comirnaty vaccine and the Prevnar-13 pneumonia vaccine are generating significant revenue, Pfizer is working to discover, research, and commercialize the next line of breakthrough drugs. Pfizer, for example, recently increased its research and development spending from $3.8 billion in the first half of last year to $4.5 billion this year. While no guarantee increased R&D spending will lead to the discovery of more drugs and approvals, it's the best chance pharmaceutical stocks have at innovating and staying relevant. That's why Pfizer's dividend yield of 3.7% is safe for the foreseeable future and is the best choice in its sector for stable income.
NYSE:PFEShort
by FOREXN1
9
WHETHER 200-EMA WILL STOP THE PHIZEZ SLIDING MODE?The Pfizer Inc. Stock has been in a sliding mode since August when it hit its all-time high at $51.84 per share. However, the slide was stopped yesterday from strong support 200-period Exponential moving average and 38.2 Fibo level, which prevented the stock from drifting lower. Overall, the stock continues to trade below the downside line taken from the high of September 7th, which keeps the short-term outlook negative. However, in order to get confident on a trend continuation, the experts would like to see a dip below $41.50. A decisive break below that barrier would confirm a forthcoming lower low and may initially target the $38.15 per share hurdle, defined as a support by the 23.6 Fibo corrections. If investors are not willing to buy near that price, then the price could experience declines towards the $33.44 area, which acted as a temporary floor for the stock between October 2020 and March 2021. Looking at our short-term oscillators, we see that the RSI moved lower but ticked up from slightly above 30, while the MACD, already negative, has just fallen below its trigger line. Both indicators detect downside speed, which enhances the case for further declines in this stock. The move that could change the short-term picture to positive is the subsequent rebound from 200-EMA and 38.2 corrections and a break above $42.65. This will confirm the break above the pre-mentioned downside line and a forthcoming higher high. The bulls may get encouraged to push the action towards the high around $44.84 or the peak of September 07th, at $47.52. If they don’t stop there, we could see them aiming for the all-time high above $50.00. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carry a high-risk level. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and such sites. Furthermore, one understands that the company carries zero influence over transactions, needs, and trading signals. Therefore, it cannot be held liable nor guarantee any profits or losses.
NYSE:PFE
by legacyFXofficial
What May Happen to Moderna and Pfizer?International pharmaceutical giant Merck & Co announced the successful end of its clinical trial of the world’s first oral COVID-19 antiviral drug molnupiravir in the simple form of a pill. The company has claimed that molnupiravir effectively decreases the risk of hospitalization and death of sick individuals who have just contracted the virus or have advanced symptoms by half.  Moreover, the company also suggested that molnupiravir could be used to prevent the contraction of  the coronavirus. But what is most important at this stage is that fact that the clinical trials of molnupiravir showed high effectiveness against different COVID-19 variants, including the terrifying Delta variant. This seems to be good news for antivaxers or for anybody who is looking for an alternative prevention method from COVID-19 other than the vaccine.  Whether you agree or disagree with having the vaccine, it is worthwhile to consider this information as a means of expanding your investment portfolio with Merck stocks. Additionally, COVID-19 major vaccine producers Pfizer and Moderna stocks may suffer if the new pill is officially registered. Let’s take a look at Pfizer and Moderna’s price charts. Both stocks suffered a 50% correction from their peaks in August. Although, Pfizer business model is more diversified than that of Moderna’s, the technical picture shows that the upward trend for Pfizer stocks is more in danger. The reason for such fears is that over the last three consecutive trading sessions its stocks closed below the trend support line that started in February 2021. So, if Pfizer stock prices fail to recover above the $43.20-44 correction, they are likely to continue towards the $38.20-39.20 area. In this area, two important technical lines cross – one is the support line of the upward trend that started in March 2020 and the second – former resistance line that connects September 2020 and May, June 2021 highs. Pfizer and BioNTEch may have a trump of positive opinion by the Committee for Medicinal Products for Human Use (CHMP) for the administration of the Pfizer-BioNTech COVID-19 vaccine as a booster shot six months after the second dose, but this factor is already priced in. The Moderna stock prices chart seems to be more complex as it shows that the March 2020 long-term upward trend is supported by the upward trend that started in May 2021 in the area of $319-321. Even the correction from the peak of $496.71 closely echoes the ABC correction structure, where A and C waves are equal. And if so, Moderna stocks may recover both not only to recent highs, but to new all-time highs. Such a scenario might be activated if prices hold above the downward channel from August 10. In this case new targets may open at $563-565. Technical perspectives of Merck stocks will be reviewed in the coming comments.
NASDAQ:MRNALong
by scavoanastasiia
4
Pfizer | Fundamental Analysis | Short view Many would agree that a half victory is better than a total defeat. Pfizer and BioNTech have seen this through firsthand experience. The two partners had hoped that an FDA advisory committee would recommend revaccination with the COVID-19 vaccine to all Americans 16 years of age and older. A week ago, however, the committee voted 16-2 against recommending the Pfizer-BioNTech vaccine for a wide age range. It wasn't just bad news for these drug companies, however. The FDA advisory committee also voted unanimously to recommend the boosters for U.S. citizens age 65 and older, and anyone at high risk for severe COVID-19. And now you're probably wondering, could Pfizer stock be a reasonable investment choice after this partial victory? The FDA still has to decide whether to revaccinate the Pfizer-BioNTech vaccine. If the agency follows the commission's recommendations and the Centers for Disease Control and Prevention (CDC) agrees with them, many additional vaccines could soon become available. As per the U.S. Department of Health and Human Services' Office on Aging, there were about 52.4 million Americans age 65 and older in 2018. Today, that number is undoubtedly higher. Vaccination rates among older Americans are higher than any other age group. According to the CDC, nearly 85 percent of people between the ages of 65 and 74 have been fully vaccinated. Nearly 80% of Americans age 75 and older have been fully vaccinated. We don't know how many of these people received the Comirnaty COVID-19 vaccine from Pfizer and BioNTech. However, overall, Comirnaty accounts for about 57% of all COVID-19 vaccine doses administered to date. It is estimated that about 25 million Comirnaty revaccinations could be administered in the following months if the FDA and CDC give the green light to revaccination. Based on previous vaccine prices, the total cost of revaccination for the groups recommended by the FDA panel could approach $500 million. At first glance, the possibility of an additional $500 million over the next few months may seem significant. However, there are several reasons not to get so excited. Most importantly, none of the companies are likely to get "extra" money from boosters shortly. The U.S. has already ordered a total of 500 million doses from Pfizer and BioNTech, plus another 500 million doses for transfer to other countries. At least at this time, it is doubtful that extra doses will be purchased by the government to vaccinate Americans. Keep in mind also that Pfizer and BioNTech share profits from Comirnaty. Even if the companies could expect additional orders from the U.S. government for boosters, the financial impact for Pfizer would not be huge. In the second quarter, the company had revenue of $19 billion and profits of nearly $5.6 billion. There is really no good reason to buy Pfizer stock based on the recommendation of the FDA advisory committee. Nevertheless, there are other reasons why investors might seriously consider stock in this major pharmaceutical company. The need for an annual refill for everyone is still a real possibility. If Pfizer can count on strong recurring revenues from Comirnaty for years to come, the stock will look much more attractive. No doubt, Pfizer doesn't just rely on its COVID-19 vaccine. The pharmaceutical giant has other growth drivers that should appeal to investors, notably the rare heart disease drug Vyndaqel/Vyndamax and the blood-thinning drug Eliquis. Pfizer's pipeline could bring even more big wins. A pill for COVID-19 may be on the way. The drugmaker also has more than 20 other late-stage programs. It is also adding to its portfolio through deals, including intentions to buy Trillium Therapeutics. Last, but not least, is Pfizer's dividend. Many income investors will like the dividend yield, which is currently 3.5%. For some investors, Pfizer stock looks like a good choice. But any endorsement for older Americans boosters isn't much of a factor in deciding whether or not to buy the stock one way or the other.
PShort
by FOREXN1
3
Pfizer dropping momentumFibgoals fractally at origin of Wave 5 of impulse and then beyond. If our mapping is correct, this impulse is done for now. Remember, this is not financial advice. You must do your own research and carefully make decisions for yourself by yourself. We love TA and do not provide individually tailored financial advice, or financial advice period. Now that aside, Fibonacci in crystal clear green and invalidation noted, as always, in red. Good luck out there.
NYSE:PFEShort
by Rykin_Capital
BULLISH IMPULSE IS COMING 💉✅PREVIOUSLY ON PFE We were expecting that A was broken and it's broken. ✅ WHERE WE ARE We have expected the drop to 43.27(Fib61.8). If the price is rejected around Fib61.8, we can expect the bullish impulsive wave. *As long as 37.96 remains unbroken, this idea is valid. 💡The absolute principle for trading💡 BUY - as low as possible SELL - as high as possible PLEASE DO NOT FORGET TO SMASH LIKE👍🏻 AND FOLLOW ME❤ IT MOTIVATES ME TO THE NEXT IDEA! THANK YOU 🎉
NYSE:PFELong
by waveslover
PFE Daily TimeframeSNIPER STRATEGY (new version) It works ALMOST ON ANY CHART. It produces Weak, Medium and Strong signals based on consisting elements. NOT ALL TARGETS CAN BE ACHIEVED, let's make that clear. TARGETS OR ENTRY PRICES ARE STRONG SUPPORT AND RESISTANCE LEVELS. ENTRY PRICE BLACK COLOR TARGETS GREEN COLOR STOP LOSS RED COLOR DO NOT USE THIS STROTEGY FOR LEVERAGED TRADING. It will not give you the whole wave like any other strategy out there but it will give you a huge part of the wave. The BEST TIMEFRAMES for this strategy are Daily, Weekly and Monthly however it can work on any timeframe. Consider those points and you will have a huge advantage in the market. There is a lot more about this strategy. It can predict possible target and also give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts. START BELIEVING AND GOOD LUCK HADIMOZAYAN
NYSE:PFEShort
by hadimozayan
PFIZER Daily TimeframeSNIPER STRATEGY This magical strategy works like a clock on almost any charts Although I have to say it can’t predict pullbacks, so I do not suggest this strategy for leverage trading. It will not give you the whole wave like any other strategy out there but it will give you huge part of the wave. The best timeframe for this strategy is Daily, Weekly and Monthly however it can work any timeframe above three minutes. Start believing in this strategy because it will reward believers with huge profit. There is a lot more about this strategy. It can predict and also it can give you almost exact buy or sell time on the spot. I am developing it even more so stay tuned and start to follow me for more signals and forecasts.
NYSE:PFEShort
by hadimozayan
2
DROPPING WELL AS EXPECTED. READY FOR THE 3RD BOOST? 👁️ 💉✅PREVIOUSLY ON PFE We were expecting that A was broken and it's broken. ✅ WHERE WE ARE Because A is broken, it's confirmed that 47.50 is B. If so, we should recognize the C, at which bearish 5 waves would be formed after B. As of now, 43.27(Fib61.8) looks like the good long entry point to ride the next boost. *As long as 37.96 remains unbroken, this idea is valid. 💡The absolute principle for trading💡 BUY - as low as possible SELL - as high as possible PLEASE DO NOT FORGET TO SMASH LIKE👍🏻 AND FOLLOW ME❤ IT MOTIVATES ME TO THE NEXT IDEA! THANK YOU 🎉
NYSE:PFE
by waveslover
PFIZER: FUNDAMENTAL ANALYSIS + NEXT TARGET POINT ⚡️As you know, Pfizer's biggest product at the moment is the coronavirus vaccine, Comirnati. The company and its partner BioNTech expect it to bring in more than $33 billion this year. Meanwhile, Pfizer expects revenue from the coronavirus vaccine to account for 42% of the company's total revenue. The vaccine is certainly one good reason to buy stock in this major pharmaceutical giant. But there is another reason to buy Pfizer stock, and it has nothing to do with the COVID-19 vaccine. It is important to remember that Pfizer has a huge number of commercialized products, including seven blockbuster drugs. Earlier this month, one of them received good news - news that should prompt us to take a closer look at this pharmaceutical company's stock. Eliquis, the blood-thinning drug commercialized by Pfizer and its partner Bristol Myers Squibb, received a very important decision in the appeals court. The court upheld the original decision protecting the patents on this best-selling drug, including the drug's composition and formula. This means that the generic drugmaker will not be able to enter the market with a competing drug until April 2028. Pfizer and Bristol Myers will probably file another appeal, but after two courts have already ruled in their favor, one can be optimistic about their case. This is great news for Pfizer, given the revenue generated from the sale of the drug Eliquis. Last year, Pfizer reported more than $4.9 billion in revenue from the alliance and direct sales of the drug Eliquis. That's a 17% increase over the previous year. And this was during a pandemic when access to non-COVID health care was limited. Eliquis continues to be one of Pfizer's biggest drugs. In the second quarter of this year, Eliquis generated more than $1.4 billion in revenue. That's a 16% increase over the previous year, and Eliquis was Pfizer's second-largest drug after the coronavirus vaccine. Of course, generic competition will eventually lead to lower sales of this blockbuster drug. But the court ruling gives Pfizer seven years to develop products that can replace Eliquis as a major source of revenue. Pfizer has a lot of development going on. One of the most interesting candidates is an oral drug to treat the coronavirus. It would be a pill that people could take within days of the first symptoms, and it could be a game-changer and generate billions of dollars in revenue. Pfizer began Phase 2/3 trials in July and plans to present data in the fourth quarter. The company also recently began a Phase 3 trial of a vaccine candidate against respiratory syncytial infection. Currently, there is no vaccine against this common cause of severe respiratory disease. Should you buy Pfizer stock because of news about the Eliquis patent? It's not the only reason to buy the stock, but it's one great reason. Add to that the recurring earnings from the coronavirus program. And let's not forget the company's other blockbusters. Let's not forget the drugs and vaccines that could bring in a lot of revenue in the future. All of this together is a solid recipe for success over time. Pfizer stock is up 25% and is currently outperforming the S&P 500 Index. However, the stock is hardly reflective of all the positives now and in the future. They are trading at 11 times earnings estimates. By that measure, the stock is cheap today. Pfizer stock is far behind biotech players in the coronavirus vaccine space such as its own partner BioNTech and rival Moderna. You can't be sure that the situation will change. It's much easier to quickly raise the price of a company with less market value than a major pharmaceutical player. But over time, Pfizer has serious potential to increase revenues and profits -- and that should match the stock's rise. This month's news on the Eliquis patent is a huge step in the right direction.
NYSE:PFELong
by FOREXN1
4
PFE STILL MORE GAS IN THE TANKThis chart has been fairly predictable for the past year, however as we start to shape up the larger degree wave count, I've decided to alter this from an expanding diagonal to a typical impulse. The main thing shaping this is the action for wave 2 which appears to be a flat. Under this premise, we have subdivision of wave 3 underway. It appears to be an expanded third: triggering the 1.618 with evidence of another leg up to the 2.272 at $56. This is the primary trade at hand, as we target 15-20% gains here. This trade presents a 10:1 RR with a SL around $45.50 at the recent low for a 20% target. Wave 4 of 3 looks to be complete, hitting the 1.618 extension of A to B (see chart below). We have RSI testing the 70 which will be telling: if it can get into overbought territory, then it's indication of a trend reversal (as markets typically only go into overbought when bullish). Not pictured is the stacking bullish divergence for this wave 4. Another thing that stands out as evidence of wave 4 complete is that it was sharper than wave 2 of 3. By rule of alternation, we would expect this. Upon hitting this target near $56, we will reevaluate, likely close, and look for the next wave down. For now, I have a $45 level identified (w4 larger count) and a 2.618 target near $60 (w5 larger count) on the map. Remember: for extended wave 3s that approach the 2.0, we look for the next fib level near 2.618 for w5. These future targets are dependent on what happens here in this wave 3.
NYSE:PFELong
by warrenbudget
9